RecruitingPhase 4NCT05034432

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

Prophylactic Intra-Operative Ventricular Arrhythmia Ablation in High-Risk LVAD Candidates (PIVATAL)


Sponsor

University of Rochester

Enrollment

100 participants

Start Date

May 27, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate the effect of VTA ablation at the time of LVAD implant to see if it can reduce the incidence of VTA after surgery


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (PIVATAL) examines whether performing a catheter-based procedure to eliminate the source of dangerous heart rhythm abnormalities (ventricular tachycardia/fibrillation ablation) at the same time as implanting a left ventricular assist device (LVAD, a mechanical heart pump) can reduce future dangerous arrhythmias. You may be eligible if: - You are over 18 years old - You have advanced heart disease and are eligible for an LVAD - You have (or are planned to have) an implantable cardioverter defibrillator (ICD) - You have a history of sustained ventricular tachycardia (VT) or fibrillation (VF) in the past 5 years You may NOT be eligible if: - You had a prior successful ablation for VT/VF with no recurrence before LVAD implant - You are currently in another interventional clinical trial - You are unable or unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREIntra-Op Prophylactic VT ablation

For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping

OTHERConventional Management

To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued


Locations(19)

Banner University Medical Center

Phoenix, Arizona, United States

UCLA Cardiac Arrthmia Center

Los Angeles, California, United States

University of California San Francisco

San Francisco, California, United States

Medstar Washington Hospital Center

Washington D.C., District of Columbia, United States

Piedmont Heart Institute

Atlanta, Georgia, United States

Emory University

Atlanta, Georgia, United States

Ascension St. Vincent Indianapolis

Indianapolis, Indiana, United States

Univedrsity of Louisville

Louisville, Kentucky, United States

Johns Hopkins University

Baltimore, Maryland, United States

Tufts Medical Center

Boston, Massachusetts, United States

Henry Ford Health

Detroit, Michigan, United States

Columbia University Medical Center

New York, New York, United States

University of Rochester

Rochester, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

UPMC

Pittsburgh, Pennsylvania, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Houston Methodist Hospital

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05034432


Related Trials